1. Lagathu C, Cossarizza A, Bereziat V, Nasi M, Capeau J, Pinti M. Basic science and pathogenesis of ageing with HIV: potential mechanisms and biomarkers. AIDS 2017; 31 Suppl 2: S105-S19.
  2. Kirby Institute. HIV, viral hepatitis and sexually transmissible infections in Australia: Annual Surveillance Report 2018. Available at: Accessed December 14th.
  3. Guaraldi G, Palella FJ, Jr. Clinical implications of aging with HIV infection: perspectives and the future medical care agenda. AIDS 2017; 31 Suppl 2: S129-S35.
  4. Negredo E, Back D, Blanco JR, et al. Aging in HIV-Infected Subjects: A New Scenario and a New View. Biomed Res Int 2017; 2017: 5897298.
  5. Pathai S, Bajillan H, Landay AL, High KP. Is HIV a model of accelerated or accentuated aging? J Gerontol A Biol Sci Med Sci 2014; 69(7): 833-42.
  6. Sabin CA, Reiss P. Epidemiology of ageing with HIV: what can we learn from cohorts? AIDS 2017; 31 Suppl 2: S121-S8.
  7. Nasi M, De Biasi S, Gibellini L, et al. Ageing and inflammation in patients with HIV infection. Clin Exp Immunol 2017; 187(1): 44-52.
  8. Smith JM, Flexner C. The challenge of polypharmacy in an aging population and implications for future antiretroviral therapy development. AIDS 2017; 31 Suppl 2: S173-S84.
  9. Althoff KN, Smit M, Reiss P, Justice AC. HIV and ageing: improving quantity and quality of life. Curr Opin HIV AIDS 2016; 11(5): 527-36.
  10. Karpiak SE, Havlik R. Are HIV-Infected Older Adults Aging Differently? Interdiscip Top Gerontol Geriatr 2017; 42: 11-27.
  11. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12(12): 1365-71.
  12. Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5(10): e203.
  13. Schouten J, Wit FW, Stolte IG, et al. Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study. Clin Infect Dis 2014; 59(12): 1787-97.
  14. Guaraldi G, Orlando G, Zona S, et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis 2011; 53(11): 1120-6.
  15. Kennedy BK, Berger SL, Brunet A, et al. Geroscience: linking aging to chronic disease. Cell 2014; 159(4): 709-13.
  16. Australian Law Reform Commission. Available at: Accessed Dec 14.
  17. Rowe JW, Kahn RL. Human aging: usual and successful. Science 1987; 237(4811): 143-9.
  18. Deelen J, Beekman M, Capri M, Franceschi C, Slagboom PE. Identifying the genomic determinants of aging and longevity in human population studies: progress and challenges. Bioessays 2013; 35(4): 386-96.
  19. De Francesco D, Wit FW, Burkle A, et al. Do people living with HIV experience greater age advancement than their HIV-negative counterparts? AIDS 2019; 33(2): 259-68.
  20. Burdo TH, Lentz MR, Autissier P, et al. Soluble CD163 made by monocyte/macrophages is a novel marker of HIV activity in early and chronic infection prior to and after anti-retroviral therapy. J Infect Dis 2011; 204(1): 154-63.
  21. Dolan SE, Hadigan C, Killilea KM, et al. Increased cardiovascular disease risk indices in HIV-infected women. J Acquir Immune Defic Syndr 2005; 39(1): 44-54.
  22. Duprez DA, Neuhaus J, Kuller LH, et al. Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS One 2012; 7(9): e44454.
  23. Pathai S, Lawn SD, Gilbert CE, et al. Accelerated biological ageing in HIV-infected individuals in South Africa: a case-control study. AIDS 2013; 27(15): 2375-84.
  24. Payne BA, Wilson IJ, Hateley CA, et al. Mitochondrial aging is accelerated by anti-retroviral therapy through the clonal expansion of mtDNA mutations. Nat Genet 2011; 43(8): 806-10.
  25. Horvath S, Levine AJ. HIV-1 Infection Accelerates Age According to the Epigenetic Clock. J Infect Dis 2015; 212(10): 1563-73.
  26. Pathai S, Shiels PG, Weiss HA, et al. Ocular parameters of biological ageing in HIV-infected individuals in South Africa: relationship with chronological age and systemic biomarkers of ageing. Mech Ageing Dev 2013; 134(9): 400-6.
  27. Montano M, Bhasin S, D'Aquila RT, et al. Harvard HIV and Aging Workshop: Perspectives and Priorities from Claude D. Pepper Centers and Centers for AIDS Research. AIDS Res Hum Retroviruses 2019; 35(11-12): 999-1012.
  28. U.S Department of Health and Human Services. Considerations for Antiretroviral Use in Special Patient Populations: HIV and the older person. Available at: Accessed Jan 10.
  29. Stirrup OT, Copas AJ, Phillips AN, et al. Predictors of CD4 cell recovery following initiation of antiretroviral therapy among HIV-1 positive patients with well-estimated dates of seroconversion. HIV Med 2018; 19(3): 184-94.
  30. Croxford S, Kitching A, Desai S, et al. Mortality and causes of death in people diagnosed with HIV in the era of highly active antiretroviral therapy compared with the general population: an analysis of a national observational cohort. Lancet Public Health 2017; 2(1): e35-e46.
  31. Edwards JK, Cole SR, Westreich D, et al. Age at Entry Into Care, Timing of Antiretroviral Therapy Initiation, and 10-Year Mortality Among HIV-Seropositive Adults in the United States. Clin Infect Dis 2015; 61(7): 1189-95.
  32. Lodi S, Costagliola D, Sabin C, et al. Effect of Immediate Initiation of Antiretroviral Treatment in HIV-Positive Individuals Aged 50 Years or Older. J Acquir Immune Defic Syndr 2017; 76(3): 311-8.
  33. Molina JM, Grund B, Gordin F, et al. Which HIV-infected adults with high CD4 T-cell counts benefit most from immediate initiation of antiretroviral therapy? A post-hoc subgroup analysis of the START trial. Lancet HIV 2018; 5(4): e172-e80.
  34. Steinman MA, Hanlon JT. Managing medications in clinically complex elders: "There's got to be a happy medium". JAMA 2010; 304(14): 1592-601.
  35. Marzolini C, Back D, Weber R, et al. Ageing with HIV: medication use and risk for potential drug-drug interactions. J Antimicrob Chemother 2011; 66(9): 2107-11.
  36. Brown TT, Hoy J, Borderi M, et al. Recommendations for evaluation and management of bone disease in HIV. Clin Infect Dis 2015; 60(8): 1242-51.
  37. Mocroft A, Lundgren JD, Ross M, et al. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study. Lancet HIV 2016; 3(1): e23-32.
  38. Grund B, Baker JV, Deeks SG, et al. Relevance of Interleukin-6 and D-Dimer for Serious Non-AIDS Morbidity and Death among HIV-Positive Adults on Suppressive Antiretroviral Therapy. PLoS One 2016; 11(5): e0155100.
  39. Carr A, Kerr SJ, Richardson R, et al. Prolonged Effect of Zoledronic Acid on Bone Mineral Density and Turnover in HIV-Infected Adults on Tenofovir: A Randomized, Open-Label Study. J Bone Miner Res 2019; 34(12): 2192-7.
  40. Mallon PW. Aging with HIV: osteoporosis and fractures. Curr Opin HIV AIDS 2014; 9(4): 428-35.
  41. Centre for Metabolic Bone Diseases UoS, UK. FRAX® WHO Fracture Risk Assessment Tool. Available at: Accessed Jan 15.
  42. European AIDS Clinical Society. EACS Guidelines Version 10.0 November 2019. Available at: Accessed Jan 10.
  43. Carr A, Grund B, Schwartz AV, et al. The rate of bone loss slows after 1-2 years of initial antiretroviral therapy: final results of the Strategic Timing of Antiretroviral Therapy (START) bone mineral density substudy. HIV Med 2020; 21(1): 64-70.
  44. Stellbrink HJ, Orkin C, Arribas JR, et al. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis 2010; 51(8): 963-72.
  45. Martin A, Bloch M, Amin J, et al. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial. Clin Infect Dis 2009; 49(10): 1591-601.
  46. Duvivier C, Kolta S, Assoumou L, et al. Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. AIDS 2009; 23(7): 817-24.
  47. Brown TT, Moser C, Currier JS, et al. Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir. J Infect Dis 2015; 212(8): 1241-9.
  48. Bolland MJ, Grey AB, Horne AM, et al. Annual zoledronate increases bone density in highly active antiretroviral therapy-treated human immunodeficiency virus-infected men: a randomized controlled trial. J Clin Endocrinol Metab 2007; 92(4): 1283-8.
  49. Byun JH, Jang S, Lee S, et al. The Efficacy of Bisphosphonates for Prevention of Osteoporotic Fracture: An Update Meta-analysis. J Bone Metab 2017; 24(1): 37-49.
  50. Hoy JF, Richardson R, Ebeling PR, et al. Zoledronic acid is superior to tenofovir disoproxil fumarate-switching for low bone mineral density in adults with HIV. AIDS 2018; 32(14): 1967-75.
  51. Milburn J, Jones R, Levy JB. Renal effects of novel antiretroviral drugs. Nephrol Dial Transplant 2017; 32(3): 434-9.
  52. Ryom L, Kirk O, Lundgren JD, et al. Advanced chronic kidney disease, end-stage renal disease and renal death among HIV-positive individuals in Europe. HIV Med 2013; 14(8): 503-8.
  53. Campbell LJ, Ibrahim F, Fisher M, Holt SG, Hendry BM, Post FA. Spectrum of chronic kidney disease in HIV-infected patients. HIV Med 2009; 10(6): 329-36.
  54. Yombi JC, Pozniak A, Boffito M, et al. Antiretrovirals and the kidney in current clinical practice: renal pharmacokinetics, alterations of renal function and renal toxicity. AIDS 2014; 28(5): 621-32.
  55. Calza L, Sachs M, Colangeli V, et al. Prevalence of chronic kidney disease among HIV-1-infected patients receiving a combination antiretroviral therapy. Clin Exp Nephrol 2019; 23(11): 1272-9.
  56. Hou J, Nast CC. Changing concepts of HIV infection and renal disease. Curr Opin Nephrol Hypertens 2018; 27(3): 144-52.
  57. Kooij KW, Vogt L, Wit F, et al. Higher Prevalence and Faster Progression of Chronic Kidney Disease in Human Immunodeficiency Virus-Infected Middle-Aged Individuals Compared With Human Immunodeficiency Virus-Uninfected Controls. J Infect Dis 2017; 216(6): 622-31.
  58. Gupta SK, Post FA, Arribas JR, et al. Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials. AIDS 2019; 33(9): 1455-65.
  59. Arya V, Florian J, Marcus KA, Reynolds KS, Lewis LL, Sherwat AI. Does an increase in serum creatinine always reflect renal injury? The case of Stribild(R). J Clin Pharmacol 2013.
  60. Maggi P, Montinaro V, Mussini C, et al. Novel antiretroviral drugs and renal function monitoring of HIV patients. AIDS Rev 2014; 16(3): 144-51.
  61. Naggie S, Swiderska-Syn M, Choi S, et al. Markers of Tissue Repair and Cellular Aging Are Increased in the Liver Tissue of Patients With HIV Infection Regardless of Presence of HCV Coinfection. Open Forum Infect Dis 2018; 5(7): ofy138.
  62. Chan AW, Patel YA, Choi S. Aging of the Liver: What This Means for Patients with HIV. Curr HIV/AIDS Rep 2016; 13(6): 309-17.
  63. Althoff KN, Gebo KA, Moore RD, et al. Contributions of traditional and HIV-related risk factors on non-AIDS-defining cancer, myocardial infarction, and end-stage liver and renal diseases in adults with HIV in the USA and Canada: a collaboration of cohort studies. Lancet HIV 2019; 6(2): e93-e104.
  64. Sitar DS. Aging issues in drug disposition and efficacy. Proc West Pharmacol Soc 2007; 50: 16-20.
  65. Rockstroh JK, Mohr R, Behrens G, Spengler U. Liver fibrosis in HIV: which role does HIV itself, long-term drug toxicities and metabolic changes play? Curr Opin HIV AIDS 2014; 9(4): 365-70.
  66. Thompson AJ. Australian recommendations for the management of hepatitis C virus infection: a consensus statement. Med J Aust 2016; 204(7): 268-72.
  67. Maurice JB, Patel A, Scott AJ, Patel K, Thursz M, Lemoine M. Prevalence and risk factors of nonalcoholic fatty liver disease in HIV-monoinfection. AIDS 2017; 31(11): 1621-32.
  68. Ahmed MH, Woodward C, Mital D. Metabolic clinic for individuals with HIV/AIDS: a commitment and vision to the future of HIV services. Cardiovasc Endocrinol 2017; 6(3): 109-12.
  69. Guaraldi G, Lonardo A, Maia L, Palella FJ, Jr. Metabolic concerns in aging HIV-infected persons: from serum lipid phenotype to fatty liver. AIDS 2017; 31 Suppl 2: S147-S56.
  70. Sterling RK, Smith PG, Brunt EM. Hepatic steatosis in human immunodeficiency virus: a prospective study in patients without viral hepatitis, diabetes, or alcohol abuse. J Clin Gastroenterol 2013; 47(2): 182-7.
  71. Bernal E, Masia M, Padilla S, Gutierrez F. High-density lipoprotein cholesterol in HIV-infected patients: evidence for an association with HIV-1 viral load, antiretroviral therapy status, and regimen composition. AIDS Patient Care STDS 2008; 22(7): 569-75.
  72. Ahmed MH, Husain NE, Almobarak AO. Nonalcoholic Fatty liver disease and risk of diabetes and cardiovascular disease: what is important for primary care physicians? J Family Med Prim Care 2015; 4(1): 45-52.
  73. Price JC, Seaberg EC, Latanich R, et al. Risk factors for fatty liver in the Multicenter AIDS Cohort Study. Am J Gastroenterol 2014; 109(5): 695-704.
  74. National Cholesterol Education Program Expert Panel on Detection E, Treatment of High Blood Cholesterol in A. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106(25): 3143-421.
  75. Feinstein MJ, Hsue PY, Benjamin LA, et al. Characteristics, Prevention, and Management of Cardiovascular Disease in People Living With HIV: A Scientific Statement From the American Heart Association. Circulation 2019; 140(2): e98-e124.
  76. Triant VA, Perez J, Regan S, et al. Cardiovascular Risk Prediction Functions Underestimate Risk in HIV Infection. Circulation 2018; 137(21): 2203-14.
  77. Grant I, Atkinson JH, Hesselink JR, et al. Evidence for early central nervous system involvement in the acquired immunodeficiency syndrome (AIDS) and other human immunodeficiency virus (HIV) infections. Studies with neuropsychologic testing and magnetic resonance imaging. Ann Intern Med 1987; 107(6): 828-36.
  78. Nightingale S, Winston A. Measuring and managing cognitive impairment in HIV. AIDS 2017; 31 Suppl 2: S165-S72.
  79. Heaton RK, Clifford DB, Franklin DR, Jr., et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 2010; 75(23): 2087-96.
  80. Mind Exchange Working G. Assessment, diagnosis, and treatment of HIV-associated neurocognitive disorder: a consensus report of the mind exchange program. Clin Infect Dis 2013; 56(7): 1004-17.
  81. Saloner R, Heaton RK, Campbell LM, et al. Effects of comorbidity burden and age on brain integrity in HIV. AIDS 2019; 33(7): 1175-85.
  82. Canizares S, Cherner M, Ellis RJ. HIV and aging: effects on the central nervous system. Semin Neurol 2014; 34(1): 27-34.
  83. Vance DE, Wadley VG, Crowe MG, Raper JL, Ball KK. Cognitive and Everyday Functioning in Older and Younger Adults with and without HIV. Clin Gerontol 2011; 34(5): 413-26.
  84. Abas M, Nyamayaro P, Bere T, et al. Feasibility and Acceptability of a Task-Shifted Intervention to Enhance Adherence to HIV Medication and Improve Depression in People Living with HIV in Zimbabwe, a Low Income Country in Sub-Saharan Africa. AIDS Behav 2018; 22(1): 86-101.
  85. Sundermann EE, Erlandson KM, Pope CN, et al. Current Challenges and Solutions in Research and Clinical Care of Older Persons Living with HIV: Findings Presented at the 9th International Workshop on HIV and Aging. AIDS Res Hum Retroviruses 2019; 35(11-12): 985-98.
  86. Ellis RJ, Badiee J, Vaida F, et al. CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS 2011; 25(14): 1747-51.
  87. Munoz-Moreno JA, Fumaz CR, Ferrer MJ, et al. Nadir CD4 cell count predicts neurocognitive impairment in HIV-infected patients. AIDS Res Hum Retroviruses 2008; 24(10): 1301-7.
  88. Valcour V, Yee P, Williams AE, et al. Lowest ever CD4 lymphocyte count (CD4 nadir) as a predictor of current cognitive and neurological status in human immunodeficiency virus type 1 infection--The Hawaii Aging with HIV Cohort. J Neurovirol 2006; 12(5): 387-91.
  89. Valcour V, Sithinamsuwan P, Letendre S, Ances B. Pathogenesis of HIV in the central nervous system. Curr HIV/AIDS Rep 2011; 8(1): 54-61.
  90. Heaton RK, Marcotte TD, Mindt MR, et al. The impact of HIV-associated neuropsychological impairment on everyday functioning. J Int Neuropsychol Soc 2004; 10(3): 317-31.
  91. Woods SP, Moore DJ, Weber E, Grant I. Cognitive neuropsychology of HIV-associated neurocognitive disorders. Neuropsychol Rev 2009; 19(2): 152-68.
  92. Brew BJ, Chan P. Update on HIV dementia and HIV-associated neurocognitive disorders. Curr Neurol Neurosci Rep 2014; 14(8): 468.
  93. Su T, Wit FW, Caan MW, et al. White matter hyperintensities in relation to cognition in HIV-infected men with sustained suppressed viral load on combination antiretroviral therapy. AIDS 2016; 30(15): 2329-39.
  94. Anthony IC, Ramage SN, Carnie FW, Simmonds P, Bell JE. Accelerated Tau deposition in the brains of individuals infected with human immunodeficiency virus-1 before and after the advent of highly active anti-retroviral therapy. Acta Neuropathol 2006; 111(6): 529-38.
  95. Barclay TR, Hinkin CH, Castellon SA, et al. Age-associated predictors of medication adherence in HIV-positive adults: health beliefs, self-efficacy, and neurocognitive status. Health Psychol 2007; 26(1): 40-9.
  96. Woods SP, Dawson MS, Weber E, et al. Timing is everything: antiretroviral nonadherence is associated with impairment in time-based prospective memory. J Int Neuropsychol Soc 2009; 15(1): 42-52.
  97. Gisslen M, Price RW, Nilsson S. The definition of HIV-associated neurocognitive disorders: are we overestimating the real prevalence? BMC Infect Dis 2011; 11: 356.
  98. Atkinson JH, Heaton RK, Patterson TL, et al. Two-year prospective study of major depressive disorder in HIV-infected men. J Affect Disord 2008; 108(3): 225-34.
  99. Ma Q, Vaida F, Wong J, et al. Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients. J Neurovirol 2016; 22(2): 170-8.
  100. Ciccarelli N, Fabbiani M, Di Giambenedetto S, et al. Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients. Neurology 2011; 76(16): 1403-9.
  101. Conde DM, Silva ET, Amaral WN, et al. HIV, reproductive aging, and health implications in women: a literature review. Menopause 2009; 16(1): 199-213.
  102. Russell DB. Sexual function and dysfunction in older HIV-positive individuals. Sex Health 2011; 8(4): 502-7.
  103. Cohen MS, Chen YQ, McCauley M, et al. Antiretroviral Therapy for the Prevention of HIV-1 Transmission. N Engl J Med 2016; 375(9): 830-9.
  104. Cook R, Davidson P, clinical a, Martin R, Centre ND. Antiretroviral treatment can reduce the risk of HIV transmission between male partners to 'zero'. BMJ 2019; 366: l4915.
  105. Rodger AJ, Cambiano V, Bruun T, et al. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. Lancet 2019; 393(10189): 2428-38.
  106. Basson R, Schultz WW. Sexual sequelae of general medical disorders. Lancet 2007; 369(9559): 409-24.
  107. Lindau ST, Schumm LP, Laumann EO, Levinson W, O'Muircheartaigh CA, Waite LJ. A study of sexuality and health among older adults in the United States. N Engl J Med 2007; 357(8): 762-74.
  108. Wilson TE, Jean-Louis G, Schwartz R, et al. HIV infection and women's sexual functioning. J Acquir Immune Defic Syndr 2010; 54(4): 360-7.
  109. Golub SA BM, Gamarel KE, Parsons JT, Brennan MW, Karpiak SE. . Dimensions of psychological well-being predict consistent condom use among older adults living with HIV. Ageing Int 2011; 36(346): 179-94.
  110. Rueda S, Law S, Rourke SB. Psychosocial, mental health, and behavioral issues of aging with HIV. Curr Opin HIV AIDS 2014; 9(4): 325-31.
  111. ANTHONY LYONS (a1) SCa, CATHERINE BARRETT (a1) and CAROLYN WHYTE (a1). Growing Old as a Gay Man: Psychosocial Well-Being of a Sexual Minority. Ageing & Society 2014; 35(10): pp. 2229-50.
  112. Lubben J, Blozik E, Gillmann G, et al. Performance of an abbreviated version of the Lubben Social Network Scale among three European community-dwelling older adult populations. Gerontologist 2006; 46(4): 503-13.
  113. Antonucci TC, Ajrouch KJ, Birditt KS. The convoy model: explaining social relations from a multidisciplinary perspective. Gerontologist 2014; 54(1): 82-92.
  114. Medicine AaNZSfG. Position Statement No. 8 Comprehensive Geriatric Assessment and Community Practice. Available at: Accessed Jan 21 2020.
  1. Work Group for HIV, Aging Consensus P. Summary report from the Human Immunodeficiency Virus and Aging Consensus Project: treatment strategies for clinicians managing older individuals with the human immunodeficiency virus. J Am Geriatr Soc 2012; 60(5): 974-9.
  2. Piggott DA, Erlandson KM, Yarasheski KE. Frailty in HIV: Epidemiology, Biology, Measurement, Interventions, and Research Needs. Curr HIV/AIDS Rep 2016; 13(6): 340-8.
  3. Yeoh HL, Cheng AC, Cherry CL, et al. Immunometabolic and Lipidomic Markers Associated With the Frailty Index and Quality of Life in Aging HIV+ Men on Antiretroviral Therapy. EBioMedicine 2017; 22: 112-21.
  4. Rockwood K, Mitnitski A. Frailty in relation to the accumulation of deficits. J Gerontol A Biol Sci Med Sci 2007; 62(7): 722-7.
  5. Yeoh HL, Cheng A, Palmer C, Crowe SM, Hoy JF. Frailty in men living with HIV: a cross-sectional comparison of three frailty instruments. Antivir Ther 2018; 23(2): 117-27.
  6. Longenberger A, Lim JY, Brown TT, et al. Low physical function as a risk factor for incident diabetes mellitus and insulin resistance. Future Virol 2011; 6(4): 439-49.
  7. Erlandson KM, Allshouse AA, Jankowski CM, et al. Risk factors for falls in HIV-infected persons. J Acquir Immune Defic Syndr 2012; 61(4): 484-9.
  8. Erlandson KM, Allshouse AA, Jankowski CM, et al. Comparison of functional status instruments in HIV-infected adults on effective antiretroviral therapy. HIV Clin Trials 2012; 13(6): 324-34.
  9. Akgun KM, Tate JP, Crothers K, et al. An adapted frailty-related phenotype and the VACS index as predictors of hospitalization and mortality in HIV-infected and uninfected individuals. J Acquir Immune Defic Syndr 2014; 67(4): 397-404.
  10. Cesari M, Vellas B, Hsu FC, et al. A physical activity intervention to treat the frailty syndrome in older persons-results from the LIFE-P study. J Gerontol A Biol Sci Med Sci 2015; 70(2): 216-22.
  11. Pahor M, Guralnik JM, Ambrosius WT, et al. Effect of structured physical activity on prevention of major mobility disability in older adults: the LIFE study randomized clinical trial. JAMA 2014; 311(23): 2387-96.
  12. Kelaiditi E, van Kan GA, Cesari M. Frailty: role of nutrition and exercise. Curr Opin Clin Nutr Metab Care 2014; 17(1): 32-9.
  13. Bierman AS. Functional status: the six vital sign. J Gen Intern Med 2001; 16(11): 785-6.
  14. The Academy of Medical Sciences. Multimorbidity: a priority for global health research. Available at: Accessed Jan 10.
  15. Edmiston N, Passmore E, Smith DJ, Petoumenos K. Multimorbidity among people with HIV in regional New South Wales, Australia. Sex Health 2015; 12(5): 425-32.
  16. Allavena C, Hanf M, Rey D, et al. Antiretroviral exposure and comorbidities in an aging HIV-infected population: The challenge of geriatric patients. PLoS One 2018; 13(9): e0203895.
  17. Gnjidic D, Hilmer SN, Blyth FM, et al. Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. J Clin Epidemiol 2012; 65(9): 989-95.
  18. Marzolini C, Gibbons S, Khoo S, Back D. Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications. J Antimicrob Chemother 2016; 71(7): 1755-8.
  19. Wellons MF, Sanders L, Edwards LJ, Bartlett JA, Heald AE, Schmader KE. HIV infection: treatment outcomes in older and younger adults. J Am Geriatr Soc 2002; 50(4): 603-7.
  20. Wutoh AK, Elekwachi O, Clarke-Tasker V, Daftary M, Powell NJ, Campusano G. Assessment and predictors of antiretroviral adherence in older HIV-infected patients. J Acquir Immune Defic Syndr 2003; 33 Suppl 2: S106-14.
  21. Silverberg MJ, Leyden W, Horberg MA, DeLorenze GN, Klein D, Quesenberry CP, Jr. Older age and the response to and tolerability of antiretroviral therapy. Arch Intern Med 2007; 167(7): 684-91.
  22. Gellad WF, Grenard JL, Marcum ZA. A systematic review of barriers to medication adherence in the elderly: looking beyond cost and regimen complexity. Am J Geriatr Pharmacother 2011; 9(1): 11-23.
  23. Duff PK, Money DM, Ogilvie GS, et al. Severe menopausal symptoms associated with reduced adherence to antiretroviral therapy among perimenopausal and menopausal women living with HIV in Metro Vancouver. Menopause 2018; 25(5): 531-7.
  24. Fick DM, Semla TP. 2012 American Geriatrics Society Beers Criteria: new year, new criteria, new perspective. J Am Geriatr Soc 2012; 60(4): 614-5.
  25. Detering K, Silvester W, Corke C, et al. Teaching general practitioners and doctors-in-training to discuss advance care planning: evaluation of a brief multimodality education programme. BMJ Support Palliat Care 2014; 4(3): 313-21.
  26. Detering KM, Hancock AD, Reade MC, Silvester W. The impact of advance care planning on end of life care in elderly patients: randomised controlled trial. BMJ 2010; 340: c1345.
  27. Mosack KE, Wandrey RL. Discordance in HIV-positive patient and health care provider perspectives on death, dying, and end-of-life care. Am J Hosp Palliat Care 2015; 32(2): 161-7.
  28. Wenger NS, Kanouse DE, Collins RL, et al. End-of-life discussions and preferences among persons with HIV. JAMA 2001; 285(22): 2880-7.
  29. Detering K, Sutton E, Fraser S, et al. Feasibility and acceptability of advance care planning in elderly Italian and Greek speaking patients as compared to English-speaking patients: an Australian cross-sectional study. BMJ Open 2015; 5(8): e008800.